Australian drug development company Invion Limited (ASX: IVX) will be hosting investor briefings across Brisbane, Melbourne and Sydney in June, featuring presentations from Professor Richard Bond, PhD, Professor of Pharmacology, University of Houston (USA); Invion Chief Medical Officer Dr Mitchell Glass; and Managing Director and Chief Executive Officer, Dr Greg Collier.
The investor briefings will be an opportunity for Australian investors to gain insight to:
- The science behind the paradigm shift that occurred with regard to the use of beta-blockers in the treatment of chronic heart failure, and Invion’s repurposing of beta-blocker INV102 (nadolol) as a treatment for airway diseases; and
- Invion’s development strategy underpinning the Company’s respiratory drug franchise for INV102 (nadolol) and INV104 (zafirlukast); and the development of INV103 (ala-Cpn10).
Currently a Professor of Pharmacology at the University of Houston, Professor Bond is a pioneering expert on using beta-blockers as a potential treatment for chronic airway diseases. Professor Bond is highly regarded in the scientific community with published papers in top scientific journals including Nature and Science. He has received numerous awards and honours throughout his esteemed career and is the recipient of an ongoing grant from the National Institutes of Health (NIH) to study the effects of nadolol in individuals with asthma.
Dr Mitchell Glass, who leads Invion’s clinical development, will present alongside Professor Bond. Dr Glass successfully led the development of the beta-blocker and chronic heart failure therapy carvedilol through to FDA approval, and he will be sharing his expertise on this medical, regulatory and commercial precedent to the development of nadolol.
At the conclusion of the roadshow, Invion intends to release a Boardroom Radio interview with Dr Glass and Professor Bond highlighting key points from their presentations.
About Invion Limited: Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol), a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX)with its clinical headquarters in Delaware, USA. FOR MORE INFORMATION CONTACT Managing Director and CEO: Dr Greg Collier via firstname.lastname@example.org